Abstract: SA-PO444
Polycystic Kidney Disease Is Significantly Associated with Alzheimer Dementia RiskPropensity Score Matched Analysis of a Nationwide, Population-Base Cohort
Session Information
- CKD: Cognitive Dysfunction, Depression, Quality of Life
November 04, 2017 | Location: Hall H, Morial Convention Center
Abstract Time: 10:00 AM - 10:00 AM
Category: Chronic Kidney Disease (Non-Dialysis)
- 306 CKD: Cognitive Dysfunction, Depression, Quality of Life
Authors
- Yu, Tung-Min, Taichung Veterans General Hospital, Taichung ---, Taiwan
- Chuang, Ya-Wen, Taichung Veterans General Hospital, Taichung ---, Taiwan
- Moriishi, Misaki, Tsuchiya General Hospital, Hiroshima, Hiroshima, Japan
- Tsuchiya, Shinichiro, Tsuchiya General Hospital, Hiroshima, Hiroshima, Japan
Background
Data on the risk of neurodegenerative diseases, including Alzheimer disease and Parkinson disease, in patients with polycystic kidney disease (PKD) are lacking.
Methods
A total of 4229 patients who were aged ≥20 years and had received a diagnosis of PKD were included in the PKD cohort. For each PKD case identified, 1 participant aged ≥20 years without a history of PKD, dementia, or PD was selected from the comparison cohort. For each patient with PKD, the corresponding controls were selected 1:1 on the basis of the nearest propensity score calculated using logistic regression.
Results
The incidence density rates of dementia were 4.31 and 2.50 per 1000 person-years in the PKD and control cohorts, respectively. A 2.04-fold higher risk of dementia was observed in patients with PKD than in controls (adjusted hazard ratio [aHR] = 2.04; 95% confidence interval [CI] = 1.46–2.85). Regarding the risk of different dementia subtypes including AD and vascular dementia (VD), the aHR for AD and pre-senile dementia was 2.71 (95% CI = 1.08–6.75) and that for VD was 0.90 (95% CI = 0.43–1.87) in patients with PKD compared with controls, after adjustment for age, sex, and comorbidities. Compared with controls, the risk of PD increased by 1.78-fold (95% CI = 1.14–2.79) in patients with PKD.
Conclusion
In clinical practice, health care professions should be aware of the risk of these neurodegenerative diseases in patients with PKD.